Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
The topical cream is indicated to treat impetigo, a bacterial skin infection caused by Staphylococcus aureus or Streptococcus pyogenes in both adults and paediatric patients as young as two months. In conjunction with this acquisition, Pelthos also completed a private financing round through convertible notes, bringing in $18m from current investors, including Ligand Pharmaceuticals and a consortium spearheaded by Murchinson. Terms of the latest deal require Pelthos to pay $3m to Biofrontera and $1.2m to Ferrer upfront. Further payments will depend on commercial supply levels of the cream and future sales. The agreement also includes royalty obligations by Pelthos on US net sales to both Ferrer and the investor group. Initially developed by Ferrer in collaboration with Medimetriks Pharmaceuticals, Xepi received approval from the Food and Drug Administration (FDA) in 2017, becoming the first new treatment for impetigo in more than a decade. Although Biofrontera has held righ
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- How Ligand Pharmaceuticals' Strong Q3 Results and Raised Guidance May Impact LGND Investors [Yahoo! Finance]Yahoo! Finance
- What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? [Yahoo! Finance]Yahoo! Finance
- Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
LGND
Earnings
- 11/6/25 - Beat
LGND
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/14/25 - Form SCHEDULE
- LGND's page on the SEC website